<DOC>
	<DOCNO>NCT02254993</DOCNO>
	<brief_summary>Part A : Open-label , multiple arm , safety , microbiology pharmacokinetic ( PK ) study healthy adult male female subject 18-75 year age . All subject assess safety microbiology parameter . A subset subject assess pharmacokinetic parameter . No longer enrol study subject Part A . Part B : Open-label , multiple arm , safety microbiology study healthy adult male female subject 18-75 year age . All subject assess safety , pharmacokinetic , microbiology parameter .</brief_summary>
	<brief_title>Phase 2 , Open-Label Study Safety , Microbiology PK Single Multiple Oral C16G2 Gel Doses</brief_title>
	<detailed_description>Open-label , multiple arm , safety , microbiology pharmacokinetic ( PK ) study healthy adult male female subject 18-75 year age conduct two part . Part A study evaluate 6 study arm , depend microbiology response evaluate . Before dose C16G2 , eligible subject undergo professional dental prophylaxis Day 0 . Clinic visit Study Arms include Visit 1 ( Screening/Days -21 0 ) , Treatment Visits 2 6 ( Baseline/Day 0 Day 4 ) , follow-up Visits 7 11 ( Day 5 , 8 , 12 , 19 ± 1 33 ± 2 ) . All subject assess safety microbiology parameter approximately 5 week . A subset subject Study Arms 2 4 assess pharmacokinetic parameter . Part A study longer enrol study subject . Part B study evaluate 5 study arm , depend microbiology response evaluate 2 interim microbiology review . Clinic visit study arm except Study Arm 5 include Visit 1 ( Screening/Days -21 0 ) , Visit 2 ( Baseline/Day 0 ) , Visits 3 17 ( Days 1 6 , morning evening visit , Days 7 , 10 14 ) . All subject assess safety microbiology parameter approximately 2 week . Before dose C16G2 , eligible subject undergo professional dental prophylaxis Day 0 . Study drug administer 7 consecutive day . The Sponsor perform microbiology review evaluate S. mutans response Study Arms 1 &amp; 2 , applicable , Study Arms 3a 3b . In Study Arm 5 , subject receive multiple C16G2 dos single day evaluate safety , microbiology pharmacokinetic parameter . Clinic visit Study Arm 5 include Visit 1 ( Screening/Days -21 0 ) , Visit 2 ( Baseline/Day 0 ) , Visit 3/Day 1 Visit 4/Day 6 .</detailed_description>
	<mesh_term>Dental Caries</mesh_term>
	<criteria>Inclusion Criteria ( Parts A &amp; B ) : 1 . Males female , 1875 year age , inclusive , time Informed Consent Form sign 2 . Female subject childbearing potential , define surgically sterile , must agree use one follow form contraception screen last study visit : hormonal ( oral , implant , injection ) begin &gt; 30 day prior screen ; barrier ( condom , diaphragm , cervical cap spermicide ) ; intrauterine device ( IUD ) . Acceptable contraceptive option may also include abstinence , monogamous relationship sex partner partner vasectomy least six ( 6 ) month prior screen visit 3 . Male subject : willing use contraception abstain sexual activity begin first exposure study drug continue discharge study due completion Early Termination 4 . Healthy , determine Investigator ( consultation Medical Monitor , need ) , base medical dental history , concurrent illness , laboratory result , concomitant medication , oral cavity assessment , target physical examination ( extraoral , head neck ) Screening 5 . Have minimum six unrestored bicuspid molar ≤50 % molar bicuspids restoration , crown , sealant miss 6 . Demonstrated ability expectorate ≥2mL stimulate saliva 5 minute 7 . Have salivary S. mutans 2.0 x 10e4 CFUs/mL great ( Part A ) 1.0 x 10e5 CFU/mL great ( Part B ) Screening use MSB agar plat 8 . Willing refrain use nonstudy dentifrice nonstudy oral care product study 9 . Willing postpone elective dental procedure ( e.g. , dental cleaning ) Screening final posttreatment visit ( End Study Early Termination ) 10 . Able understand sign Informed Consent Form prior initiation study procedures 11 . Able communicate Investigator/study site personnel , understand comply study requirement , willing return protocolspecified visit appoint time Exclusion Criteria ( Parts A &amp; B ) : 1 . Advanced periodontal disease 2 . Active caries lesion ( ) within 30 day prior study drug administration ( confirmed dental examination standard radiograph ) 3 . Medical condition ( e.g. , artificial heart valve , history infective endocarditis , cardiac transplant valvular dysfunction , congenital heart disease total joint replacement ) antibiotic recommend prior dental visit and/or procedure 4 . Pathologic lesion oral cavity ( suspicious confirm ) 5 . Full partial denture , orthodontic appliance , e.g. , night guard , permanent retainer 6 . Use systemic antibiotic , topical oral antibiotic , use drug , opinion Investigator could influence study outcome , within 30 day prior Screening 7 . Medical history indicate woman pregnant , breastfeeding/ lactate positive urine pregnancy test 8 . Participation clinical trial receipt nonFDA approve therapy within 30 day prior study drug administration ( depend specific , participation observational study necessarily exclude ) 9 . Prior participation C16G2 clinical trial know receive C16G2 active gel mouth rinse ( Note : placebo subject exclude ) 10 . Presence condition concurrent illness , opinion Investigator , would compromise normal immune function ( e.g. , diabetes , rheumatoid arthritis , lupus , liver disease , organ transplant , etc . ) , interfere use study dentifrice oral care product , interfere ability comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>